pegunigalsidase alfa
Selected indexed studies
- Pegunigalsidase Alfa. (, 2006) [PMID:37247361]
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. (J Med Genet, 2024) [PMID:37940383]
- A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (J Inherit Metab Dis, 2025) [PMID:39381863]
_Worker-drafted node — pending editorial review._
Connections
pegunigalsidase alfa is a side effect of
Sources
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. (2024) pubmed
- A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. (2025) pubmed
- Current status of the immunogenicity of enzyme replacement therapy in fabry disease. (2025) pubmed
- Pegunigalsidase Alfa. (2006) pubmed
- PMID:40198018 (2023) pubmed
- Pegunigalsidase Alfa-iwxj. (2023) pubmed
- Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease. (2024) pubmed
- Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. (2023) pubmed
- Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial. (2019) pubmed
- Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease. (2023) pubmed